View as cardsView as table106 Projects

Evaluating splicing modulators for therapeutic impact in cohesin-mutant AML and MDS cells

Fiscal Year Awarded:

2020

Principal Investigator:

Karen Adelman

Interleukin-17 as a novel erythropoiesis stimulating agent

Fiscal Year Awarded:

2020

Principal Investigator:

Allon Klein

Monoclonal antibody-based therapeutics for Argentine hemorrhagic fever

Fiscal Year Awarded:

2020

Principal Investigator:

Jonathan Abraham

Multiplex editing the human genome

Fiscal Year Awarded:

2020

Principal Investigator:

George Church

Next-generation AAV therapies for management of intractable chronic pain

Fiscal Year Awarded:

2020

Principal Investigator:

Michael Greenberg

Target validation and in vivo testing of a broad-spectrum antiviral

Fiscal Year Awarded:

2020

Principal Investigator:

Priscilla Yang

Targeting apoptotic pathways for ALS, Alzheimer’s Disease and Parkinson’s Disease

Fiscal Year Awarded:

2020

Principal Investigator:

Bruce Bean

A novel system for rational discovery of polycystic kidney disease therapeutics

Fiscal Year Awarded:

2019

Principal Investigator:

Adrian Salic

Computationally designed therapy targeting lysosomal function and inflammation in neurodegenerative diseases

Fiscal Year Awarded:

2019

Principal Investigator:

Peter Park

Development of a new precision therapeutic for an important cancer target

Fiscal Year Awarded:

2019

Principal Investigator:

Stephen Blacklow

Development of AAV-mediated mini-gene therapy for Usher syndrome type 1F, a combined deafness and blindness

Fiscal Year Awarded:

2019

Principal Investigator:

David Corey

Development of an inexpensive at-home influenza kit and detection technology

Fiscal Year Awarded:

2019

Principal Investigator:

Michael Springer

Development of new antiviral compounds

Fiscal Year Awarded:

2019

Principal Investigator:

Donald Coen

Isoguvacine and benzodiazepine derivatives for the treatment of tactile hypersensitivity and anxiety in autism spectrum disorders

Fiscal Year Awarded:

2019

Principal Investigator:

David Ginty

Small molecule modulators of gut bacterial bile acid metabolism to treat metabolic syndrome and associated non-alcoholic fatty liver disease (NAFLD)

Fiscal Year Awarded:

2019

Principal Investigator:

Sloan Devlin

Targeting neuro-immune signaling to treat bacterial infections

Fiscal Year Awarded:

2019

Principal Investigator:

Isaac Chiu

Developing CRISPR-Cas9 reagents for editing lytic and latent herpes simplex virus genomes

Fiscal Year Awarded:

2018

Principal Investigator:

David Knipe

Developing therapeutics for treating Rett Syndrome by correcting neuronal long-gene misregulation – Lead compound optimization and in vivo validation

Fiscal Year Awarded:

2018

Principal Investigator:

Michael Greenberg

Development of small molecule modulators of autophagy and ER stress as novel therapeutics for AD

Fiscal Year Awarded:

2018

Principal Investigator:

Junying Yuan

Identification of dengue virus inhibitors

Fiscal Year Awarded:

2018

Principal Investigator:

Priscilla Yang